PACAP Intraperitoneal Treatment Suppresses Appetite and Food Intake Via PAC1 Receptor in Mice by Inhibiting Ghrelin and Increasing GLP-1 and Leptin
Overview
Physiology
Authors
Affiliations
Pituitary adenylate cyclase-activating peptide (PACAP) is expressed within the gastroenteric system, where it has profound physiological effects. PACAP was shown to regulate food intake and thermogenesis centrally; however, PACAP peripheral regulation of appetite and feeding behavior is unknown. Therefore, we studied PACAP's effect on appetite and food intake control by analyzing feeding behavior and metabolic hormones in PAC1-deficient (PAC1-/-) and age-matched wild-type (WT) mice intraperitoneally injected with PACAP1-38 or PACAP1-27 before the dark phase of feeding. Food intake and feeding behavior were analyzed using the BioDAQ system. Active ghrelin, glucagon-like peptide-1 (GLP-1), leptin, peptide YY, pancreatic polypeptide, and insulin were measured following PACAP1-38 administration in fasted WT mice. PACAP1-38/PACAP1-27 injected into WT mice significantly decreased in a dose-dependent manner cumulative food intake and reduced bout and meal feeding parameters. Conversely, PACAP1-38 injected into PAC1-/- mice failed to significantly change food intake. Importantly, PACAP1-38 reduced plasma levels of active ghrelin compared with vehicle in WT mice. In PAC1-/- mice, fasting levels of active ghrelin, GLP-1, insulin, and leptin and postprandial levels of active ghrelin and insulin were significantly altered compared with levels in WT mice. Therefore, PAC1 is a novel regulator of appetite/satiety. PACAP1-38/PACAP1-27 significantly reduced appetite and food intake through PAC1. In PAC1-/- mice, the regulation of anorexigenic/orexigenic hormones was abolished, whereas active ghrelin remained elevated even postprandially. PACAP significantly reduced active ghrelin in fasting conditions. These results establish a role for PACAP via PAC1 in the peripheral regulation of appetite/satiety and suggest future studies to explore a therapeutic use of PACAP or PAC1 agonists for obesity treatment.
Curtis G, Carpenter B, Pirino B, Hawks A, Li G, Barson J Psychopharmacology (Berl). 2024; 242(2):413-426.
PMID: 39340653 PMC: 11774677. DOI: 10.1007/s00213-024-06692-9.
Mitragynine and morphine produce dose-dependent bimodal action on food but not water intake in rats.
Zuarth Gonzalez J, Mottinelli M, McCurdy C, de Lartigue G, McMahon L, Wilkerson J Am J Physiol Regul Integr Comp Physiol. 2024; 327(6):R568-R579.
PMID: 39250542 PMC: 11687856. DOI: 10.1152/ajpregu.00128.2024.
Curtis G, Carpenter B, Pirino B, Hawks A, Li G, Barson J Res Sq. 2024; .
PMID: 38645077 PMC: 11030496. DOI: 10.21203/rs.3.rs-4145128/v1.
PACAP and VIP Neuropeptides' and Receptors' Effects on Appetite, Satiety and Metabolism.
Vu J, Luong L, Sanford D, Oh S, Kuc A, Pisegna R Biology (Basel). 2023; 12(7).
PMID: 37508442 PMC: 10376325. DOI: 10.3390/biology12071013.
The functional heterogeneity of PACAP: Stress, learning, and pathology.
Rajbhandari A, Barson J, Gilmartin M, Hammack S, Chen B Neurobiol Learn Mem. 2023; 203:107792.
PMID: 37369343 PMC: 10527199. DOI: 10.1016/j.nlm.2023.107792.